Exploring the Potential of Selinexor and Ruxolitinib in Myelofibrosis from Karyopharm Therapeutics' Phase 3 SENTRY Trial

Executed on:Apr 20, 2026 10:00 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: McGill (Jewish General Hospital)Assistant Professor of Oncology at McGill.
Manages ~30 MF patients/month.
Established the first myeloproliferative neoplasms clinic in Canada; has authored several publications in the area of MPN clinical research and has been an investigator on several clinical trials assessing novel agents in the treatment of MPN.

Interview Goal

To gain a deeper understanding of Selinexor (XPO1 inhibitor; marketed as XPOVIO®) in Combination with Ruxolitinib for Myelofibrosis

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.